There are 2949 resources available
1320P - Impact of body mass index (BMI) in non-small cell lung cancer patients treated with anti PD-1 immunotherapy (IO): A retrospective cohort study
Presenter: Ana Catarina Bravo
Session: E-Poster Display
Resources:
Abstract
1321P - Advanced lung cancer inflammation index (ALI score) as a biomarker of immunotherapy efficacy in patients with advanced non-small cell lung cancer: A nationwide analysis in Greece
Presenter: Giannis Mountzios
Session: E-Poster Display
Resources:
Abstract
1322P - Real-world treatment patterns and immunotherapy (IO) sequencing based on PD-L1 TPS in European patients with metastatic NSCLC
Presenter: Erin Janowicz
Session: E-Poster Display
Resources:
Abstract
1323P - Natural killer cell activity as a prognostic biomarker in non-small cell lung cancer patients treated with check-point inhibitors
Presenter: Sara Wen
Session: E-Poster Display
Resources:
Abstract
1324P - Pembrolizumab as a monotherapy (P) or in combination with platinum-based chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumour proportion score (TPS) ≥50%: A real-world data (Israeli Lung Cancer Group)
Presenter: Elizabeth Dudnik
Session: E-Poster Display
Resources:
Abstract
1325P - Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world study (EVIDENS)
Presenter: Fabrice Barlesi
Session: E-Poster Display
Resources:
Abstract
1326P - Liver metastasis but not bone metastasis impact overall survival of advanced non-small cell lung cancer (NSCLC) treated by nivolumab (GFPC 04-2016)
Presenter: Chantal Decroisette
Session: E-Poster Display
Resources:
Abstract
1327P - Benchmarking the efficacy and safety of pembrolizumab plus chemotherapy to pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression
Presenter: Hiroshi Takumida
Session: E-Poster Display
Resources:
Abstract
1328P - Clinical outcomes of pembrolizumab plus chemotherapy in non-squamous metastatic NSCLC patients aged 75 years or older at US oncology practices
Presenter: Vamsidhar Velcheti
Session: E-Poster Display
Resources:
Abstract
1329P - Immune checkpoint inhibitors in advanced NSCLC patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers in a real world experience
Presenter: Riccardo Lobefaro
Session: E-Poster Display
Resources:
Abstract